UOC
AEON icon

UBS O'Connor’s AEON Biopharma AEON Stock Holding History

UBS O'Connor’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,536
Closed -$4.73M – 624
2022
Q4 		$4.73M Sell
6,536
-65
-1% -$46.6K 0.09% 199
2022
Q3 		$4.68M Sell
6,601
-663
-9% -$470K 0.05% 297
2022
Q2 		$5.13M Hold
7,264
– – 0.05% 289
2022
Q1 		$5.12M Buy
7,264
+128
+2% +$89.8K 0.06% 264
2021
Q4 		$4.99M Buy
7,136
+192
+3% +$135K 0.05% 284
2021
Q3 		$4.88M Hold
6,944
– – 0.04% 293
2021
Q2 		$4.82M Buy
+6,944
New +$4.85M 0.04% 288

Other funds holding AEON

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

UBS O'Connor's AEON Position: Q1 2023 in Review

UBS O'Connor sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 6,536 shares — an estimated $4.73M sold.

UBS O'Connor first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $5.13M in Q2 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • UBS O'Connor reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • UBS O'Connor sold 6,536 AEON Biopharma shares in Q1 2023, an estimated $4.73M.
  • UBS O'Connor first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
  • UBS O'Connor's AEON Biopharma position peaked at $5.13M in Q2 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.